⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15415294 | 0.72 | ESR2 (0.44) | — | |
| SCHEMBL16793365 | 0.70 | — | — | |
| SCHEMBL16792447 | 0.70 | — | — | |
| SCHEMBL16792392 | 0.65 | — | — | |
| SCHEMBL15415312 | 0.63 | SLC6A2 (0.44) | — | |
| SCHEMBL16794731 | 0.63 | — | — | |
| SCHEMBL15414969 | 0.62 | — | — | |
| SCHEMBL15415542 | 0.61 | — | — | |
| SCHEMBL15415965 | 0.61 | — | — | |
| SCHEMBL19410918 | 0.61 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 121 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10906919-B2 | Fused pentacyclic imidazole derivatives | UCB Biopharma SRL (BE) | 2021-02-02 | — | — | US | claimed |
| US-11912721-B2 | Fused pentacyclic imidazole derivatives | UCB Biopharma SRL (BE) | 2024-02-27 | — | — | US | disclosed |
| EP-3436456-B1 | FUSED HEXACYCLIC IMIDAZOLE DERIVATIVES AS MODULATORS OF TNF ACTIVITY | UCB Biopharma SRL (BE) | 2021-11-17 | — | — | EP | disclosed |
| EP-3436460-B1 | FUSED PENTACYCLIC IMIDAZOLE DERIVATIVES AS MODULATORS OF TNF ACTIVITY | UCB Biopharma SRL (BE) | 2021-08-18 | — | — | EP | disclosed |
| EP-3201196-B1 | FUSED PENTACYCLIC IMIDAZOLE DERIVATIVES | UCB Biopharma SRL (BE) | 2021-07-28 | — | — | EP | disclosed |
| EP-3436458-B1 | FUSED PENTACYCLIC IMIDAZOLE DERIVATIVES AS MODULATORS OF TNF ACTIVITY | UCB Biopharma SRL (BE) | 2021-06-02 | — | — | EP | disclosed |
| US-20210155637-A1 | Fused Pentacyclic Imidazole Derivatives | SANOFI (FR) | 2021-05-27 | — | — | US | disclosed |
| US-10953019-B2 | Fused pentacyclic imidazole derivatives as modulators of TNF activity | UCB Biopharma SRL (BE) | 2021-03-23 | — | — | US | disclosed |
| US-10906919-B2 | Fused pentacyclic imidazole derivatives | UCB Biopharma SRL (BE) | 2021-02-02 | — | — | US | disclosed |
| US-10793578-B2 | Fused pentacyclic imidazole derivatives as modulators of TNF activity | UCB Biopharma SRL (BE) | 2020-10-06 | — | — | US | disclosed |
| WO-2015086498-A1 | TETRAHYDROIMIDAZOPYRIDINE DERIVATIVES AS MODULATORS OF TNF ACTIVITY | UCB BIOPHARMA SPRL (BE) | 2015-06-18 | — | — | WO | disclosed |
| WO-2015086507-A1 | IMIDAZOPYRIDINE DERIVATIVES AS MODULATORS OF TNF ACTIVITY | UCB BIOPHARMA SPRL (BE) | 2015-06-18 | — | — | WO | disclosed |
| WO-2015086512-A1 | FUSED IMIDAZOLE AND PYRAZOLE DERIVATIVES AS MODULATORS OF TNF ACTIVITY | UCB BIOPHARMA SPRL (BE) | 2015-06-18 | — | — | WO | disclosed |
| WO-2015086506-A1 | FUSED IMIDAZOLE AND PYRAZOLE DERIVATIVES AS MODULATORS OF TNF ACTIVITY | UCB BIOPHARMA SPRL (BE) | 2015-06-18 | — | — | WO | disclosed |
| WO-2015086496-A1 | TRIAZOLOPYRIDINE DERIVATIVES AS MODULATORS OF TNF ACTIVITY | UCB BIOPHARMA SPRL (BE) | 2015-06-18 | — | — | WO | disclosed |
| WO-2015086526-A1 | FUSED TRICYCLIC IMIDAZOLE DERIVATIVES AS MODULATORS OF TNF ACTIVITY | UCB BIOPHARMA SPRL (BE) | 2015-06-18 | — | — | WO | disclosed |
| EP-2872508-A1 | IMIDAZOPYRIDINE DERIVATIVES AS MODULATORS OF TNF ACTIVITY | UCB Biopharma SPRL (BE) | 2015-05-20 | — | — | EP | disclosed |
| EP-2872511-A1 | IMIDAZOPYRAZINE DERIVATIVES AS MODULATORS OF TNF ACTIVITY | UCB Biopharma SPRL (BE) | 2015-05-20 | — | — | EP | disclosed |
| WO-2014009295-A1 | IMIDAZOPYRIDINE DERIVATIVES AS MODULATORS OF TNF ACTIVITY | UCB PHARMA S.A. (BE) | 2014-01-16 | — | — | WO | disclosed |
| WO-2014009296-A1 | IMIDAZOPYRAZINE DERIVATIVES AS MODULATORS OF TNF ACTIVITY | UCB PHARMA S.A. (BE) | 2014-01-16 | — | — | WO | disclosed |